{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T21:34:24Z","timestamp":1790112864533,"version":"4.0.1"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2023,3,13]],"date-time":"2023-03-13T00:00:00Z","timestamp":1678665600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,3,13]],"date-time":"2023-03-13T00:00:00Z","timestamp":1678665600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Invest New Drugs"],"published-print":{"date-parts":[[2023,4]]},"DOI":"10.1007\/s10637-023-01340-z","type":"journal-article","created":{"date-parts":[[2023,3,12]],"date-time":"2023-03-12T21:02:42Z","timestamp":1678654962000},"page":"324-332","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["A phase 1b study of the allosteric extracellular FGFR2 inhibitor alofanib in patients with pretreated advanced gastric cancer"],"prefix":"10.1007","volume":"41","author":[{"given":"Ilya","family":"Tsimafeyeu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Galina","family":"Statsenko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liubov","family":"Vladimirova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalia","family":"Besova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Artamonova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Grigory","family":"Raskin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ivan","family":"Rykov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anastasia","family":"Mochalova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Igor","family":"Utyashev","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Svetlana","family":"Gorbacheva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vasily","family":"Kazey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evgenia","family":"Gavrilova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nadezhda","family":"Dragun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vladimir","family":"Moiseyenko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sergei","family":"Tjulandin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,3,13]]},"reference":[{"key":"1340_CR1","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1007\/978-3-319-50520-6_12.Erratum.In:CurrTopMicrobiolImmunol.2017;400:E1","volume":"400","author":"C Figueiredo","year":"2017","unstructured":"Figueiredo C, Camargo MC, Leite M, Fuentes-Panan\u00e1 EM, Rabkin CS, Machado JC (2017) Pathogenesis of Gastric Cancer: Genetics and Molecular Classification. Curr Top Microbiol Immunol 400:277\u2013304. https:\/\/doi.org\/10.1007\/978-3-319-50520-6_12.Erratum.In:CurrTopMicrobiolImmunol.2017;400:E1","journal-title":"Curr Top Microbiol Immunol."},{"issue":"20","key":"1340_CR2","doi-asserted-by":"publisher","first-page":"33844","DOI":"10.18632\/oncotarget.12953","volume":"8","author":"S Seo","year":"2017","unstructured":"Seo S, Park SJ, Ryu MH et al (2017) Prognostic impact of fibroblast growth factor receptor 2 gene amplification in patients receiving fluoropyrimidine and platinum chemotherapy for metastatic and locally advanced unresectable gastric cancers. Oncotarget 8(20):33844\u201333854","journal-title":"Oncotarget."},{"issue":"11","key":"1340_CR3","doi-asserted-by":"publisher","first-page":"2560","DOI":"10.7150\/jca.29184","volume":"10","author":"HS Kim","year":"2019","unstructured":"Kim HS, Kim JH, Jang HJ (2019) Pathologic and prognostic impacts of FGFR2 amplification in gastric cancer: a meta-analysis and systemic review. J Cancer 10(11):2560\u20132567","journal-title":"J Cancer."},{"key":"1340_CR4","doi-asserted-by":"publisher","first-page":"1095","DOI":"10.1038\/modpathol.2016.96","volume":"29","author":"S Ahn","year":"2016","unstructured":"Ahn S, Lee J, Hong M et al (2016) FGFR2 in gastric cancer: protein overexpression predicts gene amplification and high H-index predicts poor survival. Mod Pathol 29:1095\u20131103","journal-title":"Mod Pathol"},{"issue":"2","key":"1340_CR5","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0264011","volume":"17","author":"T Schrumpf","year":"2022","unstructured":"Schrumpf T, Behrens HM, Haag J, Kr\u00fcger S, R\u00f6cken C (2022) FGFR2 overexpression and compromised survival in diffuse-type gastric cancer in a large central European cohort. PLoS One 17(2)","journal-title":"PLoS One."},{"issue":"7","key":"1340_CR6","doi-asserted-by":"publisher","first-page":"1703","DOI":"10.3390\/cancers13071703","volume":"13","author":"AT Sengal","year":"2021","unstructured":"Sengal AT, Smith D, Rogers R, Snell CE, Williams ED, Pollock PM (2021) Fibroblast Growth Factor Receptor 2 Isoforms Detected via Novel RNA ISH as Predictive Biomarkers for Progestin Therapy in Atypical Hyperplasia and Low-Grade Endometrial Cancer. Cancers (Basel) 13(7):1703","journal-title":"Cancers (Basel)."},{"issue":"5","key":"1340_CR7","doi-asserted-by":"publisher","first-page":"5440","DOI":"10.18632\/oncotarget.6706","volume":"7","author":"D Ranieri","year":"2016","unstructured":"Ranieri D, Rosato B, Nanni M, Magenta A, Belleudi F, Torrisi MR (2016) Expression of the FGFR2 mesenchymal splicing variant in epithelial cells drives epithelial-mesenchymal transition. Oncotarget 7(5):5440\u201360","journal-title":"Oncotarget."},{"key":"1340_CR8","doi-asserted-by":"crossref","unstructured":"Sengal AT, Bonazzi V, Kondrashova O et al (2021) Targeting FGFR2c isoform, a novel therapeutic target with FGFR inhibitor in endometrial cancer [abstract]. In: Proceedings of the AACR-NCI-EORTC Virtual International Conference on Molecular Targets and Cancer Therapeutics; 2021 Oct 7-10. Philadelphia (PA): AACR; Mol Cancer Ther 2021;20(12 Suppl): Abstract nr LBA020","DOI":"10.1158\/1535-7163.TARG-21-LBA020"},{"key":"1340_CR9","doi-asserted-by":"crossref","unstructured":"Pierce KL, Deshpande AM, Stohr BA et al (2014) FPA144, a humanized monoclonal antibody for both FGFR2-amplified and nonamplified, FGFR2b-overexpressing gastric cancer patients. JCO 32(15_suppl):e15074","DOI":"10.1200\/jco.2014.32.15_suppl.e15074"},{"issue":"2021","key":"1340_CR10","first-page":"9955456","volume":"30","author":"RJ Epstein","year":"2021","unstructured":"Epstein RJ, Tian LJ, Gu YF (2021) 2b or Not 2b: How Opposing FGF Receptor Splice Variants Are Blocking Progress in Precision Oncology. J Oncol 30(2021):9955456","journal-title":"J Oncol."},{"issue":"5","key":"1340_CR11","doi-asserted-by":"publisher","first-page":"880","DOI":"10.1038\/s41416-020-01157-0","volume":"124","author":"MA Krook","year":"2021","unstructured":"Krook MA, Reeser JW, Ernst G et al (2021) Fibroblast growth factor receptors in cancer: genetic alterations, diagnostics, therapeutic targets and mechanisms of resistance. Br J Cancer 124(5):880\u2013892","journal-title":"Br J Cancer."},{"key":"1340_CR12","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1016\/j.ejca.2016.03.068","volume":"61","author":"I Tsimafeyeu","year":"2016","unstructured":"Tsimafeyeu I, Ludes-Meyers J, Stepanova E et al (2016) Targeting FGFR2 with alofanib (RPT835) shows potent activity in tumour models. Eur J Cancer 61:20\u20138","journal-title":"Eur J Cancer."},{"issue":"2","key":"1340_CR13","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1007\/s10637-016-0404-1","volume":"35","author":"A Tyulyandina","year":"2017","unstructured":"Tyulyandina A, Harrison D, Yin W et al (2017) Alofanib, an allosteric FGFR2 inhibitor, has potent effects on ovarian cancer growth in preclinical studies. Invest New Drugs 35(2):127\u2013133","journal-title":"Invest New Drugs."},{"issue":"1","key":"1340_CR14","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1007\/s10517-015-3104-5","volume":"160","author":"DA Khochenkov","year":"2015","unstructured":"Khochenkov DA, Solomko ES, Peretolchina NM, Ryabaya OO, Stepanova EV (2015) Antiangiogenic Activity of Alofanib, an Allosteric Inhibitor of Fibroblast Growth Factor Receptor 2. Bull Exp Biol Med 160(1):84\u20137","journal-title":"Bull Exp Biol Med."},{"issue":"6","key":"1340_CR15","doi-asserted-by":"publisher","first-page":"1207","DOI":"10.1093\/annonc\/mdx081","volume":"28","author":"C Hierro","year":"2017","unstructured":"Hierro C, Alsina M, S\u00e1nchez M, Serra V, Rodon J, Tabernero J (2017) Targeting the fibroblast growth factor receptor 2 in gastric cancer: promise or pitfall? Ann Oncol 28(6):1207\u20131216","journal-title":"Ann Oncol."},{"issue":"5","key":"1340_CR16","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1016\/S1470-2045(20)30109-1","volume":"21","author":"GK Abou-Alfa","year":"2020","unstructured":"Abou-Alfa GK, Sahai V, Hollebecque A et al (2020) Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 study. Lancet Oncol 21(5):671\u2013684","journal-title":"Lancet Oncol."},{"issue":"10","key":"1340_CR17","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1016\/S2468-1253(21)00196-5","volume":"6","author":"M Javle","year":"2021","unstructured":"Javle M, Roychowdhury S, Kelley RK et al (2021) Infigratinib (BGJ398) in previously treated patients with advanced or metastatic cholangiocarcinoma with FGFR2 fusions or rearrangements: mature results from a multicentre, open-label, single-arm, phase 2 study. Lancet Gastroenterol Hepatol 6(10):803\u2013815","journal-title":"Lancet Gastroenterol Hepatol."},{"key":"1340_CR18","doi-asserted-by":"publisher","unstructured":"Lapina NV, Stosman KI, Melikhova MV et al (2019) Preclinical toxicology of alofanib, an allosteric inhibitor of fibroblast growth factor receptor 2. Malignant tumours 9(3):65-70. (In Russ.) https:\/\/doi.org\/10.18027\/2224-5057-2019-9-3-65-70","DOI":"10.18027\/2224-5057-2019-9-3-65-70"},{"issue":"10","key":"1340_CR19","doi-asserted-by":"publisher","first-page":"1005","DOI":"10.1016\/j.annonc.2022.07.004","volume":"33","author":"F Lordick","year":"2022","unstructured":"Lordick F, Carneiro F, Cascinu S et al (2022) Gastric cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann Oncol 33(10):1005\u20131020","journal-title":"Ann Oncol."},{"key":"1340_CR20","doi-asserted-by":"crossref","unstructured":"Shitara K, Doi T, Dvorkin M et al (2018) Trifluridine\/tipiracil versus placebo in patients with heavily pretreated metastatic gastric cancer (TAGS): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol 19(11):1437-1448","DOI":"10.1016\/S1470-2045(18)30739-3"},{"issue":"Supplement 5","key":"1340_CR21","doi-asserted-by":"publisher","first-page":"v122","DOI":"10.1093\/annonc\/mdy208.001","volume":"29","author":"J Tabernero","year":"2018","unstructured":"Tabernero J, Shitara K, Dvorkin M et al (2018) Overall survival results from a phase III trial of trifluridine\/tipiracil versus placebo in patients with metastatic gastric cancer refractory to standard therapies (TAGS). Ann Oncol 29(Supplement 5):v122\u2013v123. https:\/\/doi.org\/10.1093\/annonc\/mdy208.001","journal-title":"Ann Oncol."},{"issue":"4","key":"1340_CR22","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2021.100200","volume":"6","author":"J Tabernero","year":"2021","unstructured":"Tabernero J, Shitara K, Zaanan A et al (2021) Trifluridine\/tipiracil versus placebo for third or later lines of treatment in metastatic gastric cancer: an exploratory subgroup analysis from the TAGS study. ESMO Open 6(4)","journal-title":"ESMO Open."},{"issue":"11","key":"1340_CR23","doi-asserted-by":"publisher","first-page":"1430","DOI":"10.1016\/S1470-2045(22)00603-9","volume":"23","author":"ZA Wainberg","year":"2022","unstructured":"Wainberg ZA, Enzinger PC, Kang YK et al (2022) Bemarituzumab in patients with FGFR2b-selected gastric or gastro-oesophageal junction adenocarcinoma (FIGHT): a randomised, double-blind, placebo-controlled, phase 2 study. Lancet Oncol 23(11):1430\u20131440","journal-title":"Lancet Oncol."}],"container-title":["Investigational New Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-023-01340-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10637-023-01340-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-023-01340-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,4,27]],"date-time":"2023-04-27T04:08:11Z","timestamp":1682568491000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10637-023-01340-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,13]]},"references-count":23,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2023,4]]}},"alternative-id":["1340"],"URL":"https:\/\/doi.org\/10.1007\/s10637-023-01340-z","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-2511667\/v1","asserted-by":"object"}]},"ISSN":["0167-6997","1573-0646"],"issn-type":[{"value":"0167-6997","type":"print"},{"value":"1573-0646","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,3,13]]},"assertion":[{"value":"24 January 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 February 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 March 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Evgenia Gavrilova and Nadezhda Dragun are employees of Ruspharmtech LLC.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}